We can't find the internet
Attempting to reconnect
Something went wrong!
Hang in there while we get back on track
Microplastics and Nanoplastics in Human Blood: Current Evidence, Practical Measurement Limitations, and the Need for Scalable Tests for Public Health Studies and Routine Clinical Use
AI summary Read the abstract
Scientists have confirmed tiny plastic particles (microplastics and nanoplastics) are showing up in human blood, but this review shows that different labs use very different testing methods, making it hard to compare results or track how plastic exposure might affect our health over time. That matters because without a standardized, reliable blood test, we can't yet answer basic questions like how much plastic is in our bodies, whether it's increasing, or what health risks it poses, though the researchers highlight a new testing approach in development that could help solve this problem.
Microplastics (MPs) and nanoplastics (NPs) have now been reported in human blood using multiple analytical approaches, including pyrolysis–gas chromatography/mass spectrometry (Py-GC/MS), micro-Fourier transform infrared spectroscopy (µFTIR), Raman-based methods, fluorescence imaging, and Nile Red-based flow cytometry. Published studies collectively support the presence of plastic-associated material in human circulation, but they do not yet constitute a standardized blood-testing framework. Existing methods differ substantially in sample preparation, specimen volume, particle-size sensitivity, analytical output, workflow duration, and whether results are reported as polymer mass, individually characterized particles, or fluorescent events. These differences limit direct comparisons across studies and create substantial challenges for translation to longitudinal human exposure monitoring. This review examines published approaches for detecting MPs and NPs in human blood, with particular attention to their practical workflows and analytical outputs. It distinguishes instrument acquisition time from total sample-to-result time, examines limitations associated with small-volume blood sampling and dried-blood approaches, and discusses the implications of Poisson sampling when discrete particles are measured in small biological aliquots. A particle-based optical approach under development by ecotera health is presented as an emerging strategy intended to provide results for public health studies and routine clinical use.
More Papers Like This
Microplastics and Nanoplastics in Human Blood: Current Evidence, Practical Measurement Limitations, and the Need for Scalable Tests for Public Health Studies and Routine Clinical Use
AI summary Read the abstract
Scientists have found tiny plastic particles (called microplastics and nanoplastics) in human blood using several different testing methods, but this review points out that these methods don't agree with each other well enough to give us a clear, standardized picture of how much plastic is really in our bodies. This matters because without consistent, reliable testing, it's hard to know how exposure to these particles might affect our health over time, the review calls for better, more scalable tests so doctors and researchers can actually track this consistently in the future.
Emerging Analytical Methodologies for Micro- and Nano-Plastics Detection in Human Samples: Analytical Challenges and Health Risk Perspectives
AI summary Read the abstract
Scientists have found tiny plastic particles (microplastics and even smaller nanoplastics) throughout human organs and body fluids, but this review of existing research shows we still lack reliable, standardized tools to accurately measure them—different labs get different results depending on how they prepare and test samples. While lab studies suggest very small plastic particles can cause cell stress and inflammation, there isn't yet solid evidence directly linking plastic exposure to specific diseases in people—so the biggest takeaway is that we urgently need better testing methods before we can truly understand the health risks these particles pose.
Methods for identifying microplastics in human biofluids: scoping review
AI summary Read the abstract
Scientists know tiny plastic particles called microplastics can end up in our blood, urine, and other body fluids, but this review reveals a big problem: researchers are using wildly different methods to detect and measure them, making it hard to compare results across studies or trust the numbers we're seeing. This matters because without consistent, reliable testing methods, we can't accurately answer basic questions like how much plastic is actually in our bodies or whether it's harming our health—so standardizing these techniques is a critical next step before we can draw firm conclusions.
Methods for identifying microplastics in human biofluids: scoping review
AI summary Read the abstract
Tiny plastic particles called microplastics are showing up in human body fluids, and scientists are still figuring out the best way to detect and measure them. This review looked at existing studies to compare the different testing methods researchers use, finding that there's currently no standard approach—which makes it hard to know exactly how much plastic is in our bodies or compare results across studies. This matters because before we can understand the health risks of microplastics, scientists need reliable, consistent ways to detect them in the first place.
The analytical challenge of measuring micro- and nanoplastics in human tissues
AI summary Read the abstract
Scientists keep finding tiny plastic particles in human tissue, but measuring them accurately is surprisingly hard, different labs use different methods and get different results. This paper explains why better, more standardized testing tools are urgently needed before we can truly understand how much plastic is in our bodies and what it might be doing to our health.
Research digests by email
When a large batch of papers lands in the Atlas, we read through it and send a short write-up of what stood out.